David is the Co-founder, Chairman and Chief Executive of Alcentra and chairs the Alcentra European Investment Committee. David also sits on the Executive Committee of BNY Mellon Investment Management and the BNY Mellon Operating Committee.
Prior to founding Alcentra, David worked at Barclays Capital from 1995 to 2003 where he was Managing Director, Founder and Chief Investment Officer of Barclays Capital Asset Management, a wholly owned subsidiary of Barclays Group Plc and the predecessor firm of Alcentra. Whilst he was at Barclays he also set up the par loan trading business and served as a Director of the Loan Market Association (LMA) and chaired the LMA Valuation Committee.
David worked at Bankers Trust from 1992 to 1995, where he was a Vice President and head of European leveraged loan distribution. Prior to that he worked at Chemical Bank from 1987 to 1992 in New York and London, in the structured finance and loan syndication departments.
David is Chairman and Founder of the DFN Charitable Foundation; Trustee of Operation Smile UK; and Trustee of the Isabel Medical Charity.
David graduated from Birmingham University with a BSc (Hons) in Chemical Engineering.
James has been an investment manager in the City for the last 22 years. Over the last eight years he has been Governor at three schools and also an academy chain. He brings a deep understanding of the education system in the UK. James also spent a year teaching English in Pakistan.
Simon is a Senior Partner of Clyde & Co, LLP and heads up the firm's insurance practice. He also sits on their global board. Prior to this Simon was a Senior Partner at Barlow, Lyde & Gilbert LLP. Simon is married with 3 children.
Eric has worked in the field of medical research charities for over 20 years. He founded Myeloma UK in 1996 and was their Chief Executive until February 2017. Currently, Eric combines working for the Amyloidosis Research Consortium as their Head of Global Strategy with a consultancy business specialising primarily in market access and evidence development strategies.
Eric describes himself as incredibly committed and focused on improving patient outcomes and puts patients at the centre of everything he does. His career goal is to have made a significant and material impact on the quality of life of patients and the prevention and curability of rare diseases.
Central to achieving this, Eric has a strong track record of delivery and success in building multi-stakeholder research collaborations and consortia, and delivering innovative solutions to complex issues challenges and barriers standing in the way of progress.
Eric also holds several board, honorary, advisory and voluntary positions and advises numerous medical and health-focused charities on a pro bono basis. He was awarded an OBE for services to charity in the Queen’s Birthday Honours 2012.